Around 25 years ago Nelson took over one of the first digital roles Johnson & Johnson had to offer: It was mainly doing the first video calls within the pharmaceutical industry in the US. Since then, not only Nelsons roles at Johnson & Johnson changed but also Asset Management in the Pharmaceutical industry changed to become more and more digital. Furthermore, the industry is at a crossroads. Should companies further outsource their Asset Management or rely on internal expertise. While it is possible for big pharma to experiment with new technologies, generics must maintain a lean budget. But big companies rarely outsource their maintenance as well, as they must be very cost-conscious and rely on their internal maintenance crew to work efficiently. The question arises whether outsourcing is always the best solution – however, no one is currently approaching the issue from an asset management perspective.

This presentation covers:

·   

• Differences between Big Pharma and the rest of the industry e.g., in regard of outsourcing
• Can outsourcing deliver the same quality and expertise?
• Clash between Finances and Technology in many generic companies (high-end vs. saving money)
• How to prompt people to consider how to achieve a change in their capabilities
• Interdependencies with the circular nature of Asset Management processes